期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 598, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2021.120333
关键词
Silybin; Chemo-immunotherapy; Tumor microenvironment; Tumor associated fibroblasts; Immunogenic cell death
资金
- Natural Science Foundation of China [81872820]
- Natural Science Foundation of Liaoning Province [39786444-7]
- Returnees Foundation from Shenyang pharmaceutical university [GGJJ2018103]
Tumor-associated fibroblasts play a crucial role in tumor progression and response to therapy in the immunosuppressive tumor microenvironment. By delivering silybin using nano liposomes, the study successfully altered the tumor immune microenvironment and enhanced the anti-tumor immune response. Combining an immunogenic cell death inducer, liposomal doxorubicin, further improved treatment efficacy and prolonged survival duration.
Tumor-associated fibroblasts (TAFs) play an important role in tumor progression and therapeutic response, especially in the immunosuppressive tumor microenvironment (TME). To remodel immunosuppressive TME of 4T1 tumor, we developed a nano liposome to deliver silybin (SLN, an anti-liver fibrosis Chinese Traditional Medicine). Liposomal silybin (SLN/LIP) possessed a spherical shape with particle sizes of 75.2 nm, high stability, and good accumulation in the tumor site. After treated with SLN/LIP, alpha-SMA positive TAFs and the deposition of stroma were decreased significantly. SLN/LIP also changed the tumor immune microenvironment through the increase of IFN-gamma and IL-12, as well as reduced of TGF-beta, SDF-1, IL6 and TNF-alpha. Importantly, SLN/LIP enhanced the infiltration of cytotoxic T cells (CTLs) and transformed a cold tumor into a hot tumor. To achieve the higher antitumor efficacy, an immunogenic cell death (ICD) inducer, liposomal doxorubicin (DOX/LIP) was combined with SLN/LIP. The combination treatment led to trigger immunogenic tumor apoptosis, and enhance antitumor immunity, therefore, improved anti-tumor efficiency, and further prolonged survival duration. The combination of liposomal silybin and liposomal doxorubicin might be a new chemo-immunotherapy approach for triple negative breast cancer (TNBC) tumor treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据